Essex Bio-Technology Limited

SEHK:1061 Stock Report

Market Cap: HK$1.6b

Essex Bio-Technology Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Haizhou Fang

Chief executive officer

HK$1.7m

Total compensation

CEO salary percentage97.5%
CEO tenureno data
CEO ownership0.9%
Management average tenure23.9yrs
Board average tenure4.3yrs

Recent management updates

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06
Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Mar 21
Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Dec 07
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Aug 25
Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Jun 22
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30
Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31
Is Essex Bio-Technology (HKG:1061) A Risky Investment?

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13
If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04
Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23
Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

CEO Compensation Analysis

How has Haizhou Fang's remuneration changed compared to Essex Bio-Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

HK$263m

Mar 31 2024n/an/a

HK$269m

Dec 31 2023HK$2mHK$2m

HK$275m

Sep 30 2023n/an/a

HK$266m

Jun 30 2023n/an/a

HK$256m

Mar 31 2023n/an/a

HK$241m

Dec 31 2022HK$2mHK$2m

HK$225m

Sep 30 2022n/an/a

HK$274m

Jun 30 2022n/an/a

HK$323m

Mar 31 2022n/an/a

HK$334m

Dec 31 2021HK$2mHK$2m

HK$346m

Sep 30 2021n/an/a

HK$339m

Jun 30 2021n/an/a

HK$332m

Mar 31 2021n/an/a

HK$275m

Dec 31 2020HK$2mHK$2m

HK$219m

Sep 30 2020n/an/a

HK$221m

Jun 30 2020n/an/a

HK$222m

Mar 31 2020n/an/a

HK$262m

Dec 31 2019HK$2mHK$737k

HK$303m

Sep 30 2019n/an/a

HK$282m

Jun 30 2019n/an/a

HK$262m

Mar 31 2019n/an/a

HK$246m

Dec 31 2018HK$2mHK$766k

HK$231m

Sep 30 2018n/an/a

HK$210m

Jun 30 2018n/an/a

HK$189m

Mar 31 2018n/an/a

HK$178m

Dec 31 2017HK$2mHK$721k

HK$167m

Compensation vs Market: Haizhou's total compensation ($USD224.37K) is below average for companies of similar size in the Hong Kong market ($USD346.63K).

Compensation vs Earnings: Haizhou's compensation has been consistent with company performance over the past year.

CEO

Haizhou Fang (58 yo)

no data

Tenure

HK$1,744,587

Compensation

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...

Leadership Team

NamePositionTenureCompensationOwnership
Mia Je Ngiam
Founder & Chairmanno dataHK$3.23m52.76%
HK$ 832.1m
Haizhou Fang
MD & Executive Directorno dataHK$1.74m0.92%
HK$ 14.6m
Hian Leng Ngiam
Executive Director & Deputy MDno dataHK$1.80m0.36%
HK$ 5.7m
Lai Man Yau
Executive Director & Company Secretary23.9yrsHK$755.60k0.0081%
HK$ 127.9k
Qi Xue
Group Chief Scientific Officer6.7yrsno datano data

23.9yrs

Average Tenure

60yo

Average Age

Experienced Management: 1061's management team is seasoned and experienced (23.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mia Je Ngiam
Founder & Chairmanno dataHK$3.23m52.76%
HK$ 832.1m
Haizhou Fang
MD & Executive Directorno dataHK$1.74m0.92%
HK$ 14.6m
Hian Leng Ngiam
Executive Director & Deputy MD4.3yrsHK$1.80m0.36%
HK$ 5.7m
Lai Man Yau
Executive Director & Company Secretary4.3yrsHK$755.60k0.0081%
HK$ 127.9k
Chi Ying Fung
Independent Non Executive Director23.5yrsHK$250.00kno data
Mee Mooi Yeow
Independent Non Executive Director20.3yrsHK$220.00kno data
Man Sing Yan
Independent Non-Executive Director1.5yrsHK$128.33kno data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 1061's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 01:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Essex Bio-Technology Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Wei LinEverbright Securities Co. Ltd.
null nullGuoyuan Securities (HK) Ltd
Stella XingNomura Securities Co. Ltd.